About the Partnership
A Partnership With Patients at Heart
Daiichi Sankyo, Inc. and Eli Lilly and Company have entered into a collaboration to develop Effient® (prasugrel).
About Daiichi Sankyo
A global pharma innovator, Daiichi Sankyo Co., Ltd., was established in 2005 through the merger of two leading Japanese pharmaceutical companies. This integration
created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world. Daiichi Sankyo's research and development focus on thrombotic disorders, malignant neoplasm, diabetes mellitus, and autoimmune disorders. Equally important to
the company are hypertension, hyperlipidemia, atherosclerosis, and bacterial infections. For more information, visit www.daiichisankyo.com.
Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd. For more information on
Daiichi Sankyo, Inc., please visit www.dsi.com.
www.daiichisankyo.com
www.dsi.com
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own
worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Indiana, Lilly provides answers—through
medicines and information—for some of the world's most urgent medical needs.
www.lilly.com